Doxorubicin Pliva 2 mg/ml otopina za injekciju/infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

doxorubicin pliva 2 mg/ml otopina za injekciju/infuziju

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb - doksorubicinklorid - otopina za injekciju/infuziju - 2 mg/ml - urbroj: 1 ml otopine za injekciju/infuziju sadrži 2 mg doksorubicinklorida

Retsevmo Europska Unija - hrvatski - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastična sredstva - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Inlyta Europska Unija - hrvatski - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - karcinom, stanice bubrega - inhibitori протеинкиназы - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Vocabria Europska Unija - hrvatski - EMA (European Medicines Agency)

vocabria

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.